Consensus statement the Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
Yüklə 0,75 Mb. Pdf görüntüsü
|
|
www.gastrojournal.org , and at
http://dx.doi.org/10.1053/j. gastro.2016.04.006 . References 1. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Heli- cobacter pylori infection. Helicobacter 2014;19(suppl 1): 1 –5 . 2. Ford AC, Axon AT. Epidemiology of Helicobacter pylori infection and public health implications. Helicobacter 2010;15(suppl 1):1 –6 .
Goh KL, Chan WK, Shiota S, et al. Epidemiology of Helicobacter pylori infection and public health implica- tions. Helicobacter 2011;16(suppl 1):1 –9 . 4. Wang AY, Peura DA. The prevalence and incidence of Helicobacter pylori-associated peptic ulcer disease and upper gastrointestinal bleeding throughout the world. Gastrointest Endosc Clin North Am 2011;21:613 –635
. 5. Sethi A, Chaudhuri M, Kelly L, et al. Prevalence of Heli- cobacter pylori in a First Nations population in north- western
Ontario. Can
Fam Physician 2013; 59:e182
–e187 . 6. Cheung J, Goodman KJ, Girgis S, et al. Disease mani- festations of Helicobacter pylori infection in Arctic Can- ada: using
epidemiology to address community concerns. BMJ Open 2014;4:e003689 . 7.
of Helicobacter pylori in the Alaska native population and association with low serum ferritin levels in young adults. Clin Diagn Lab Immunol 2000;7:885 –888
. 8. Woodward M, Morrison C, McColl K. An investigation into factors associated with Helicobacter pylori infection. J Clin Epidemiol 2000;53:175 –181 .
McColl KE. Clinical practice. Helicobacter pylori infec- tion. N Engl J Med 2010;362:1597 –1604 .
Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353 –1367
. 11.
Hunt R, Fallone C, Veldhuyzan van Zanten S, et al. Canadian Helicobacter Study Group Consensus Con- ference: update on the management of Helicobacter pylori
—an evidence-based evaluation of six topics rele- vant to clinical outcomes in patients evaluated for H pylori infection. Can J Gastroenterol 2004;18:547 –554
. 12.
Hunt RH, Fallone CA, Thomson AB. Canadian Heli- cobacter pylori Consensus Conference update: in- fections in adults. Canadian Helicobacter Study Group. Can J Gastroenterol 1999;13:213 –217 .
Malfertheiner P, Megraud F, O ’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56:772 –781
. 14.
Gisbert JP, Calvet X. Review article: Helicobacter pylori- negative duodenal ulcer disease. Aliment Pharmacol Ther 2009;30:791 –815
. 15.
Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348:g3174 . 16. Chiba N, Van Zanten SJ, Sinclair P, et al. Treating Heli- cobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET- Hp) randomised controlled trial.
BMJ 2002;
324:1012 –1016
. 17.
Moayyedi P, Soo S, Deeks JJ, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2011:CD002096 . 18. Loo VG, Fallone CA, De Souza E, et al. In-vitro suscep- tibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. J Antimicrob Chemother 1997;40:881 –883 .
Lahaie RG, Gaudreau C. Helicobacter pylori antibiotic resistance: trends over time. Can J Gastroenterol 2000; 14:895 –899
. 20.
Best L, Cooper-Lesins G, Haldane D, et al. Helicobacter pylori antibiotic resistance in Canadian populations (abstr S1293). Gastroenterology 2004;126:A-189 . 21. Luther J, Higgins PD, Schoenfeld PS, et al. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: systematic review and meta-analysis of ef ficacy and tolerability. Am J Gastro- enterol 2010;105:65 –73 .
Venerito M, Krieger T, Ecker T, et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple 64 Fallone et al Gastroenterology Vol. 151, No. 1 therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013;88:33 –45 .
McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimi- crobial resistance, and treatment outcomes for Heli- cobacter pylori infections. Ann Intern Med 2003; 139:463 –469
. 24.
Saad RJ, Chey WD. Persistent Helicobacter pylori infection after a course of antimicrobial therapy —what’s next? Clin Gastroenterol Hepatol 2008;6:1086 –1090 . 25. Peterson WL, Fendrick AM, Cave DR, et al. Helicobacter pylori-related disease: guidelines for testing and treat- ment. Arch Intern Med 2000;160:1285 –1291
. 26.
Dore MP, Leandro G, Realdi G, et al. Effect of pre- treatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori ther- apy: a meta-analytical approach. Dig Dis Sci 2000; 45:68 –76
. 27.
Chen Y-I, Fallone CA. A 14-day course of triple therapy is superior to a 10-day course for the eradication of Heli- cobacter pylori: A Canadian study conducted in a “real
world ” setting. Can J Gastroenterol Hepatol 2015; 29:e7 –e10
. 28.
Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013;12:CD008337 . 29. Lee M, Kemp JA, Canning A, et al. A randomized controlled trial of an enhanced patient compliance pro- gram for Helicobacter pylori therapy. Arch Intern Med 1999;159:2312 –2316 .
O ’Connor A, Gisbert JP, McNamara D, et al. Treatment of Helicobacter pylori infection 2010. Helicobacter 2010; 15(suppl 1):46 –52 .
Graham DY, Lew GM, Malaty HM, et al. Factors in flu-
encing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493 –496 .
Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59:1143 –1153
. 33.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924 –926
. 34.
Sultan S, Falck-Ytter Y, Inadomi JM. The AGA Institute process for developing clinical practice guidelines part one: grading the evidence. Clin Gastroenterol Hepatol 2013;11:329 –332 .
Nguyen GC, Bernstein CN, Bitton A, et al. Consensus statements on the risk, prevention, and treatment of venous thromboembolism in in flammatory bowel dis- ease: Canadian
Association of Gastroenterology. Gastroenterology 2014;146:835 –848.e6
. 36.
Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the
Toronto consensus. Gastroenterology 2015;148:1035 –1058.e3 . 37. Cook DJ, Greengold NL, Ellrodt AG, et al. The relation between systematic reviews and practice guidelines. Ann Intern Med 1997;127:210 –216
. 38.
Dalkey N. An experimental study of group opinion: the Delphi method. Futures 1969;1:408 –426 .
Guyatt GH, Oxman AD, Kunz R, et al. Going from evi- dence to recommendations. BMJ 2008;336:1049 –1051 .
van Zanten SV, Desai S, Best L, et al. Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection. Can J Gastroenterol 2010; 24:303
–306 . 41. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its rela- tionship to antibiotic consumption. Gut 2013;62:34 –42
. 42.
Lee SK, Lee SW, Park JY, et al. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. Hel- icobacter 2011;16:410 –414
. 43.Shaikh T, Fallone CA. Effectiveness of second- through sixth-line salvage Helicobacter pylori treatment: bismuth quadruple therapy is almost always a reasonable choice. Can J Gastroenterol Hepatol 2015 Nov 2. pii: 17152. http://dx.doi.org/10.1155/2016/7321574. [Epub ahead of print]
44. Gisbert JP, Calvet X. Review article: non-bismuth quadruple (concomitant) therapy for eradication of Heli- cobacter pylori. Aliment Pharmacol Ther 2011;34:604 –617 .
Gisbert JP, Molina-Infante J, Harb Y, et al. Nonbismuth quadruple (concomitant) therapy for eradication of H. pylori: standard vs. optimized (14-day, high-dose PPI) regimen
(abstr Su1172).
Gastroenterology 2014;
146:S394 –S395
. 46.
Filipec Kanizaj T, Katicic M, Skurla B, et al. Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronida- zole
triple-therapy regimens. Helicobacter 2009;
14:29 –35
. 47.
Wenzhen Y, Yumin L, Quanlin G, et al. Is antimicrobial susceptibility testing necessary before first-line treat- ment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern
Med 2010;
49:1103 –1109
. 48.
Shiota S, Reddy R, Alsarraj A, et al. Antibiotic resistance of Helicobacter pylori among male United States veter- ans. Clin Gastroenterol Hepatol 2015;13:1616 –1624
. 49.
Agudo S, Perez-Perez G, Alarcon T, et al. High preva- lence of clarithromycin-resistant Helicobacter pylori strains and risk factors associated with resistance in Madrid. Spain. J Clin Microbiol 2010;48:3703 –3707 .
Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2015;13:895 –905.e5
. 51.
Cheung J, Morse AL, Goodman KJ, et al. Prevalence of Helicobacter pylori and antibiotic resistance in an aboriginal population in Canada ’s arctic: preliminary re- sults from the Aklavik H. pylori project (abstr M1058). Gastroenterology 2009;136:A341 . 52.
Liao J, Zheng Q, Liang X, et al. Effect of fluoroquinolone resistance on 14-day levo floxacin triple and triple plus bismuth quadruple therapy. Helicobacter 2013; 18:373
–377 . 53. Katelaris PH, Forbes GM, Talley NJ, et al. A randomized comparison of quadruple and triple therapies for July 2016 Toronto Consensus for H pylori Treatment 65
Helicobacter pylori eradication: the QUADRATE Study. Gastroenterology 2002;123:1763 –1769 .
Laine L, Hunt R, El-Zimaity H, et al. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clari- thromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98:562 –567 .
Molina-Infante J, Pazos-Pacheco C, Vinagre-
Rodriguez G, et al. Nonbismuth quadruple (concomitant) therapy: empirical and tailored ef ficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin- resistant strains. Helicobacter 2012;17:269 –276 .
Fischbach LA, Goodman KJ, Feldman M, et al. Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis. Int J Epidemiol 2002; 31:128
–139 . 57. Wu JY, Liou JM, Graham DY. Evidence-based recom- mendations for successful Helicobacter pylori treatment. Expert Rev Gastroenterol Hepatol 2014;8:21 –28
. 58.
Graham DY, Shiotani A. Which therapy for Helicobacter pylori infection? Gastroenterology 2012;143:10 –12 .
Graham DY.
Hp-normogram (normo-graham) for assessing the outcome of H. pylori therapy: effect of resistance, duration, and CYP2C19 genotype. Heli- cobacter 2016;21:85 –90 .
Graham DY, Lee YC, Wu MS. Rational Helicobacter py- lori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177 –186.e3; discussion e12–e13 . 61. Uygun A, Kadayifci A, Safali M, et al. The ef ficacy of
bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. J Dig Dis 2007;8:211 –215 .
Lu H, Zhang W, Graham DY. Bismuth-containing quadruple therapy for Helicobacter pylori: lessons from China. Eur J Gastroenterol Hepatol 2013;25:1134 –1140
. 63.
Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med 2008;31:213 –224
. 64.
Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011;377:905 –913 .
Gisbert JP. Helicobacter pylori eradication: a new, single-capsule bismuth-containing quadruple therapy. Nat Rev Gastroenterol Hepatol 2011;8:307 –309
. 66.
O ’Morain C, Borody T, Farley A, et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metro- nidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multi- centre study. Aliment Pharmacol Ther 2003;17:415 –420 .
Gisbert JP, Barrio J, Modolell I, et al. Helicobacter pylori first-line and rescue treatments in the presence of peni- cillin allergy. Dig Dis Sci 2015;60:458 –464
. 68.
Essa AS, Kramer JR, Graham DY, et al. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing “concomitant therapy” versus triple therapy for Heli- cobacter
pylori eradication. Helicobacter 2009;
14:109 –118
. 69.
Gisbert JP, McNicholl AG. Eradication of Helicobacter pylori infection with non-bismuth quadruple concomitant therapy. In: Talebi Bezmin Abadi A, ed. Helicobacter pylori: to be or not to be! Sharjah, UAE: Bentham, 2016 . 70.
Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ
2013; 347:f4587 . 71.
Huang YK, Wu MC, Wang SS, et al. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. J Dig
Dis 2012;
13:232 –238
. 72.
Wu DC, Hsu PI, Wu JY, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection. Clin Gastroenterol Hepatol 2010; 8:36
–41.e1 . 73. Georgopoulos SD, Xirouchakis E, Zampeli E, et al. A randomised study comparing 10 days concomitant and sequential treatments for the eradication of Heli- cobacter pylori, in a high clarithromycin resistance area (abstr Su1152). Gastroenterology 2015;148:S-422 . 74. Molina-Infante J, Lucendo AJ, Angueira T, et al. Opti- mised empiric triple and concomitant therapy for Heli- cobacter pylori eradication in clinical practice: the OPTRICON
study. Aliment
Pharmacol Ther
2015; 41:581
–589 . 75. Rodgers C, van Zanten SV. A meta-analysis of the suc- cess rate of Helicobacter pylori therapy in Canada. Can J Gastroenterol 2007;21:295 –300
. 76.
Fallone CA, Barkun AN, Szilagyi A, et al. Prolonged treatment duration is required for successful Heli- cobacter pylori eradication with proton pump inhibitor triple therapy in Canada. Can J Gastroenterol 2013; 27:397 –402
. 77.
Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradi- cation of Helicobacter pylori using one-week triple ther- apies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996;1:138 –144 .
Assem M, El Azab G, Rasheed MA, et al. Ef ficacy and safety of levo floxacin, clarithromycin, and esomeprazol as first line triple therapy for Helicobacter pylori eradi- cation in Middle East. Prospective, randomized, blind, comparative, multicenter study. Eur J Intern Med 2010; 21:310 –314
. 79.
Molina-Infante J, Perez-Gallardo B, Fernandez- Bermejo M, et al. Clinical trial: clarithromycin vs. levo- floxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2010;31:1077 –1084 .
Qian J, Ye F, Zhang J, et al. Levo floxacin-containing triple and sequential therapy or standard sequential therapy as the first line treatment for Helicobacter pylori eradication in China. Helicobacter 2012;17:478 –485 .
Liou JM, Lin JT, Chang CY, et al. Levo floxacin-based and clarithromycin-based triple therapies as first-line and 66 Fallone et al Gastroenterology Vol. 151, No. 1 second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut 2010;59:572 –578
. 82.
O ’Connor A, Taneike I, Nami A, et al. Helicobacter pylori resistance rates for levo floxacin, tetracycline and rifa- butin among Irish isolates at a reference centre. Ir J Med Sci 2013;182:693 –695 .
Karczewska E, Klesiewicz K, Wojtas-Bonior I, et al. Levo
floxacin resistance of Helicobacter pylori strains isolated from patients in southern Poland, between 2006-2012. Acta Pol Pharm 2014;71:477 –483
. 84.
Phan TN, Santona A, Tran VH, et al. High rate of levo- floxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori
in Vietnam. Int J Antimicrob Agents 2015;45:244 –248 .
Eng NF, Ybazeta G, Chapman K, et al. Antimicrobial susceptibility of Canadian isolates of Helicobacter pylori in Northeastern Ontario. Can J Infect Dis Med Microbiol 2015;26:137 –144 .
Berning M, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylori therapy? Therap Adv Gastro- enterol 2011;4:103 –114
. 87.
Khawcharoenporn T, Vasoo S, Ward E, et al. High rates of quinolone resistance among urinary tract infections in the ED. Am J Emerg Med 2012;30:68 –74
. 88.
Lee YJ, Liu HY, Lin YC, et al. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosoco- mial infection is correlated with levo Yüklə 0,75 Mb. Dostları ilə paylaş:
|